-
C651965-2mgCUDC-427 is a potent second-generation pan-selective IAP antagonist, used for treatment of various cancers.In VitroGDC-0917 (0.1 nM-10 μM) induces reduction of cIAP1 levels in PBMCs in a concentration-dependent manner showing greater than 80%
-
C651965-50mgCUDC-427 is a potent second-generation pan-selective IAP antagonist, used for treatment of various cancers.In VitroGDC-0917 (0.1 nM-10 μM) induces reduction of cIAP1 levels in PBMCs in a concentration-dependent manner showing greater than 80%
-
C651965-5mgCUDC-427 is a potent second-generation pan-selective IAP antagonist, used for treatment of various cancers.In VitroGDC-0917 (0.1 nM-10 μM) induces reduction of cIAP1 levels in PBMCs in a concentration-dependent manner showing greater than 80%
-
C656900-1mlCUDC-427 is a potent second-generation pan-selective IAP antagonist, used for treatment of various cancers.In VitroGDC-0917 (0.1 nM-10 μM) induces reduction of cIAP1 levels in PBMCs in a concentration-dependent manner showing greater than 80%
-
C649567-10mgCudetaxestat (BLD-0409) is a potent and orally active autotaxin (ATX) inhibitor.Form:Solid.
-
C649567-25mgCudetaxestat (BLD-0409) is a potent and orally active autotaxin (ATX) inhibitor.Form:Solid.
-
C649567-5mgCudetaxestat (BLD-0409) is a potent and orally active autotaxin (ATX) inhibitor.Form:Solid.
-
C655907-1mlCudetaxestat (BLD-0409) is a potent and orally active autotaxin (ATX) inhibitor.
-
C646404-10mgCulmerciclib is a cyclin dependent kinase (CDK) inhibitor, and has antineoplastic activity.Form:Solid.
-
C646404-25mgCulmerciclib is a cyclin dependent kinase (CDK) inhibitor, and has antineoplastic activity.Form:Solid.
-
C646404-50mgCulmerciclib is a cyclin dependent kinase (CDK) inhibitor, and has antineoplastic activity.Form:Solid.
-
C646404-5mgCulmerciclib is a cyclin dependent kinase (CDK) inhibitor, and has antineoplastic activity.Form:Solid.